TY - Jour A2 - Kazuomi Au - Takahashi，Shoko Au - Hiramatsu，Megumi Au - Hotta，Shinichi Au - Watanabe，Yukie Au - Suga，Osamu Au - Endo，Yutaka Au - Miyamori，Isamu Py - 2016年/10/24 TI - SERARA®（EPLERENONE）的安全性和抗高血压作用：日本航空市场监测的结果SP - 5091951 VL - 2016年AB - 前瞻性的Selara（EPLERENONE）的预期航天监测，是一种选择性矿物质激素受体拮抗剂，进行了确认其日本高血压治疗的安全性和疗效。还检查了ePlerenone治疗后血压的变化。患有Eplerenone-Naïve的必需高血压的患者无论使用其他抗高血压药物如何才能招募。为了检查血压变化，如果ePlerenone被禁止或脱掉标签，则排除患者。患者每天一次接受50-100毫克EPLERENONE，并观察到12周。在监测期间没有限制包括抗高血压药物的治疗。在日本，3,166名患者被包括安全分析。不良药物反应的发生率为2.4％。 The major adverse drug reactions observed were hyperkalemia (0.6%), dizziness, renal impairment, and increased serum potassium (0.2% each). The mean systolic blood pressure decreased from 152.1. ± 19.0  mmHg to 134.8 ± 15.2  mmHg at week 12, and the mean diastolic blood pressure decreased from 85.8 ± 13.7  mmHg to 77.7 ± 11.4  mmHg. There were no significant new findings regarding the type or incidence of adverse reactions, and eplerenone had a clinically significant antihypertensive effect, leading to favorable blood pressure control. SN - 2090-0384 UR - https://doi.org/10.1155/2016/5091951 DO - 10.1155/2016/5091951 JF - International Journal of Hypertension PB - Hindawi Publishing Corporation KW - ER -